



olumiant[®]

(baricitinib) tablets

PATIENT ALERT CARD



Lilly | RHEUMATOLOGY

This document is approved by the Executive Directorate of Pharmacovigilance at SFDA
NOV, 2022 v3

PATIENT ALERT CARD

Information for Patients about OLUMIANT® (baricitinib)	
This document contains important information you should be aware of before and during treatment with Olumiant.	
Keep this information with you and share it with other healthcare professionals involved in your medical care or treatment.	
Your name:	
Doctor's name (who prescribed Olumiant):	
Doctor's phone number:	

Pregnancy

- Do not take Olumiant if you are pregnant or suspect you may be pregnant.
- Use effective contraception while taking Olumiant (and for 1 week after, if you stop treatment).
- Tell your doctor immediately if you become (or wish to become) pregnant.

Infections

Olumiant may make an existing infection worse or increase the chance of you getting a new infection or increase the chance of viral reactivation. Inform your doctor immediately if you get symptoms of infection, such as:

- Fever, wounds, feeling more tired than usual, or dental problems.
- A cough that won't go away, night sweats, and weight loss. These could be symptoms of tuberculosis (an infectious disease of the lungs).
- A painful skin rash with blisters. This could be a sign of a herpes zoster infection.

Blood fat

Your doctor may check for levels of fat in the blood, such as cholesterol, while you are taking Olumiant.

Blood clots

Olumiant may cause a condition in which a blood clot forms in your leg that may travel to your lungs. Inform your doctor immediately if you experience any of the following symptoms:

- Swelling or pain in one leg

	<ul style="list-style-type: none">• Warmth or redness in one leg• Shortness of breath which is unexpected• Rapid breathing• Chest pain
--	---

**To report any side effects, please contact:
The National Pharmacovigilance Centre (NPC)
Saudi Food and Drug Authority (SFDA)**

**Unified number: 19999
Email: npc.drug@sfda.gov.sa
Website: <https://ade.sfda.gov.sa/>**

Or

**Pharmacovigilance department at
Eli Lilly and Company**

**Email:
Saudi_Pharmacovigilance@lilly.com
Phone number: 00966114617845**